By Denny JacobModerna Inc. shares rose 5.7% to $128.53 in late trading Wednesday after The Wall Street Journal reported that the company is planning to test its Covid-19 vaccine in babies 3 months to 6 months old, the youngest age group studied to date. The company said it is in the final stages of planning the study, to be called BabyCove and expected to begin enrolling as many as 700 babies in September, the Journal said. BabyCove would be the first study of Moderna's vaccine in infants younger than 6 months, the Journal said. Separately on Wednesday, health experts advising U.S. health regulators backed giving vaccines from Pfizer Inc. and BioNTech SE and from Moderna to children as young as six months old. Write to Denny Jacob at denny.jacob@wsj.com(END) Dow Jones NewswiresJune 15, 2022 16:20 ET (20:20 GMT)Copyright (c) 2022 Dow Jones & Company, Inc.

Source: Wall Street Journal June 15, 2022 21:22 UTC